Oxevision Tech Lacks Strong Safety Evidence

The Lampard Inquiry, which is investigating the deaths of more than 2,000 mental health patients in Essex over a 24-year period, has been presented with findings questioning the effectiveness of Oxevision. This technology, which uses infrared sensors and cameras to monitor patients in their rooms, has been widely implemented in mental health wards.

Concerns Over Evidence Base

Read Next in Barnet Press2 min read

Arsenal Pursue Bruno Guimaraes Amid Newcastle Rejections

Newcastle United has rejected multiple offers from Arsenal for midfielder Bruno Guimaraes, who is reportedly open to a move.

Two experts from the University of Oxford reviewed 45 studies that formed the basis for Oxevision's adoption across the NHS. As reported by the BBC, these academics concluded that the studies did not provide strong independent evidence of improved patient safety, acceptability, or cost-effectiveness. Their review identified that some of the studies included contributions from Oxevision employees or were not sufficiently comprehensive.

Prof Christl Donnelly and Dr Maria Christodoulou of Oxford University stated that further independent, randomised, and adequately controlled research is necessary before any definitive conclusions can be drawn about Oxevision's impact. One of the experts acknowledged the inherent difficulties in conducting ideal studies within mental health ward environments.

Provider's Perspective

Related Borough Coverage3 min read

Burnham launches £31bn submarine programme phase

New contracts worth £8.4bn to support 18,000 extra jobs in nuclear defence by 2030.

LIO Health, the company behind Oxevision, maintains that its technology plays a crucial role in enhancing safer inpatient mental health care. The company stated that the technology has assisted staff in responding to 1,453 safety incidents within a single trust over a four-year span, asserting that its impact has been significant.

Broader Implications

Nina Ali, a partner at law firm Hodge Jones & Allen representing over 120 bereaved families at the inquiry, commented that the expert findings indicate a lack of clear evidence that Oxevision improves patient safety or care. Hat Porter, a spokesperson for the campaign group Stop Oxevision, highlighted concerns about the absence of robust independent evidence and regulation, suggesting that technologies can be widely deployed without adequate scrutiny. Fiona Scolding KC, speaking for Oxevision, raised questions about the feasibility of implementing randomised controlled trials in mental health units.

Next Steps for the Inquiry

The Lampard Inquiry is scheduled to resume in October, at which point Baroness Lampard, the inquiry's chair, will consider whether to issue interim recommendations. The hearings are expected to continue until late 2027, with a final report anticipated in 2028. NHS England has been approached for comment.